Back to today’s briefing

Story perspectives

Brazil's Healthcare Reforms: New Regulations and Public Input

3/13/2025

32 7

Summary

Story summary

Brazil's Life Sciences and Healthcare Newsletter unveils crucial regulatory changes shaping the industry. CMED is consulting on pricing for advanced therapies, while ANVISA introduces new standards for forced degradation studies. Exciting initiatives aim to enhance local medicine production, and agencies invite public input on regulatory proposals, with participation open until 2025.

1 of 1

Story summary

Brazil's Life Sciences and Healthcare Newsletter unveils crucial regulatory changes shaping the industry. CMED is consulting on pricing for advanced therapies, while ANVISA introduces new standards for forced degradation studies. Exciting initiatives aim to enhance local medicine production, and agencies invite public input on regulatory proposals, with participation open until 2025.